Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Cipla
Moodys
Queensland Health
Julphar
Medtronic
UBS
US Department of Justice
Mallinckrodt

Generated: April 24, 2018

DrugPatentWatch Database Preview

Olanzapine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for olanzapine and what is the scope of olanzapine freedom to operate?

Olanzapine
is the generic ingredient in four branded drugs marketed by Luitpold, Sandoz Inc, Lilly, Ajanta Pharma Ltd, Apotex Inc, Aurobindo Pharma Ltd, Barr Labs Inc, Dr Reddys Labs Ltd, Invagen Pharms, Jubilant Generics, Macleods Pharms Ltd, Mylan Pharms Inc, Orchid Hlthcare, Par Pharm, Sun Pharm Inds, Torrent Pharms Llc, Alkem Labs Ltd, Hikma Pharms, Ivax Pharms Inc, Qilu Pharm Co Ltd, Teva Pharms, Torrent Pharms Ltd, and Eli Lilly Co, and is included in thirty-five NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are thirty-three drug master file entries for olanzapine. Thirty-six suppliers are listed for this compound. There is one tentative approval for this compound.
Pharmacology for olanzapine
Synonyms for olanzapine
10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
10H-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
132539-06-1
2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine #
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; Lanzac; Zyprexa
2-methyl-4-(4-methyl-1-piperazinyl)-5H-thieno[3,2-c][1,5]benzodiazepine
2-Methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-benzo[b]thieno[2,3-e][1,4]diazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),2,5,7,11,13-hexaene
5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene
5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-4-THIA-2,9-DIAZATRICYCLO[8.4.0.0(3),?]TETRADECA-1(14),2,5,7,10,12-HEXAENE
5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0(3),?]tetradeca-1(14),3(7),5,8,10,12-hexaene
5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0(3),]tetradeca-1(14),3(7),5,8,10,12-hexaene
539O061
5h-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
A806453
AB0013948
AB00639907_08
AB00639907_09
AB00639907-06
AB00639907-07
AB1008596
AC-665
AC1L1IHS
ACMC-209wx7
ACN-029909
ACT03231
AJ-112146
AK-57874
AKOS000282888
AKOS005566122
ALBB-027265
ALKS-7921
AN-6960
ANW-46937
BC206213
BCP9001021
BDBM35254
BDBM82479
BIDD:GT0332
BIDD:PXR0138
Bio-0169
BR-57874
C07322
C17H20N4S
CAS_132539-06-1
CAS-132539-06-1
CCG-100922
CHEBI:7735
CHEBI:94534
CHEMBL715
CJ-20712
CO0033
CPD000466345
CS-1114
CTK0H7090
CTK6I2959
D00454
D0V4QS
DB00334
DSSTox_CID_3388
DSSTox_GSID_23388
DSSTox_RID_77010
DTXSID9023388
EBD23216
Eli Lilly brand of olanzapine
FT-0612957
GTPL47
HMS2051H05
HMS2089M04
HMS2093I04
HMS2233F24
HMS3374L02
HMS3393H05
HMS3657I15
HSDB 8155
HY-14541
I06-0784
I960
J-006186
J10363
Jsp001969
KB-231450
KS-00000XJV
KS-1090
KSC177A9B
KVWDHTXUZHCGIO-UHFFFAOYSA-N
L000455
L005958
Lanzac
Lilly brand of olanzapine
LS-152313
LY 170053
LY-170052
LY-170053
LY170053
MCULE-1620364835
MFCD00866702
Midax
MLS000759457
MLS001165781
MLS001195646
MLS001424057
MolPort-002-885-845
MolPort-005-977-341
N7U69T4SZR
NC00172
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
NCGC00096077-05
NCGC00096077-06
NSC_4585
O0393
Oferta
Olansek
Olanzapin
olanzapina
Olanzapine Teva
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine (Zyprexa)
Olanzapine [USAN:INN]
Olanzapine [USAN:USP:INN:BAN]
Olanzapine 1.0 mg/ml in Acetonitrile
olanzapine embonate
Olanzapine for system suitability, European Pharmacopoeia (EP) Reference Standard
Olanzapine Mylan
Olanzapine Neopharma
Olanzapine, >=98% (HPLC)
Olanzapine, European Pharmacopoeia (EP) Reference Standard
Olanzapine, Pharmaceutical Secondary Standard; Certified Reference Material
Olanzapine, United States Pharmacopeia (USP) Reference Standard
olanzapinum
Olzapin
Olzapin (TN)
PL001721
PL044571
Rexapin (TN)
RT-003566
S-4287
s2493
SAM001246652
SBI-0206786.P001
SC-16244
SCHEMBL117695
SCHEMBL28763
SMR000466345
SPECTRUM1505024
ST2417070
STK634338
STL388024
Symbyax
TL8000772
Tox21_111556
Tox21_111556_1
UNII-N7U69T4SZR
US8802672, Olanzapine
Z1868057799
Zalasta
Zalasta (TN)
ZINC3873830
ZINC52957434
Zolafren
Zolafren (TN)
Zydis
Zydis (TN)
Zypadhera
Zyprexa
Zyprexa (TN)
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa Zydis
Tentative approvals for OLANZAPINE
Applicant Application No. Strength Dosage Form
➤ Sign Up➤ Sign Up5MGTABLET; ORAL

US Patents and Regulatory Information for olanzapine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms OLANZAPINE olanzapine TABLET;ORAL 076000-001 Oct 24, 2011 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc OLANZAPINE olanzapine TABLET;ORAL 076866-006 Apr 23, 2012 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Teva Pharms OLANZAPINE olanzapine TABLET;ORAL 076000-005 Oct 24, 2011 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Torrent Pharms Ltd OLANZAPINE olanzapine TABLET;ORAL 091434-002 Apr 23, 2012 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for olanzapine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-003 Sep 30, 1996 ➤ Sign Up ➤ Sign Up
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-001 Sep 30, 1996 ➤ Sign Up ➤ Sign Up
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-006 Sep 9, 1997 ➤ Sign Up ➤ Sign Up
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-005 Sep 9, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
McKesson
McKinsey
US Army
Federal Trade Commission
Queensland Health
Accenture
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.